Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

What Next For Medtech And Investors Post-Coronavirus? (<em>In Vivo</em>)

What Next For Medtech And Investors Post-Coronavirus? (In Vivo)

Related Content

A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2025 and Beyond

One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry

One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry

EMA Adopts Positive Opinions for Multiple Biosimilars

Changes to Birthright Citizenship and the Impact on Fertility and Assisted Reproduction Clinics

Amgen Files BPCIA Complaints Against Biocon, Shanghai Henlius/Organon and Hikma/Gideon Richter Regarding Denosumab Biosimilars

Kashiv BioSciences Reports Positive Topline Results for XOLAIR® Biosimilar Candidate ADL-018

BioNTech Announces Transaction to Acquire CureVac

Goodwin Advises Nektar Therapeutics on Closing of $115 Million Public Offering

Goodwin Guides Kymera Therapeutics in $750 Million Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders with Gilead Sciences

Goodwin Is Number One Law Firm for Global M&A for H1 2025

Delaware Court Awards More Than $180 Million for Breach of Commercially Reasonable Efforts Obligation in Drug Development Milestone Dispute (Westlaw Today)

Goodwin Advised Landmark Bio in Acquisition by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies

SpringWorks Therapeutics Completes Acquisition by Merck KGaA, Darmstadt, Germany to Accelerate Sustainable Growth for $3.9 Billion

Goodwin Advises ProFound Therapeutics on Strategic Collaboration with Novartis of up to $750 Million for Cardiovascular Drug Discovery

Goodwin Advises Royalty Pharma in Transactions to Provide up to $2 Billion in Funding to Revolution Medicines

Life Sciences

Technology

Medtech